RELVINCA SOFT CAPSULES 80MG

Lotus Pharmaceutical Co., Ltd. Nantou Plant (TAIWAN)🇸🇬 Health Sciences Authority

Approval Date: Jul 31, 2025
Approval ID: d52855d9c5037367
Company: Lotus Pharmaceutical Co., Ltd. Nantou Plant (TAIWAN)
Type: Therapeutic

Approval Details

Approval Id: d52855d9c5037367
Drug Name: RELVINCA SOFT CAPSULES 80MG
Product Name: RELVINCA SOFT CAPSULES 80MG
Approval Number: SIN17297P
Approval Date: 2025-07-31
Registrant: LOTUS INTERNATIONAL PTE. LTD.
Licence Holder: LOTUS INTERNATIONAL PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: CAPSULE, LIQUID FILLED
Dosage: 4.2 Posology and method of administration Posology <ul> <li>As a single agent: Adult patients The recommended regimen is: First three administrations 60 mg/m2 of body surface area, administered once weekly Subsequent administrations After the third administration, it is recommended to increase the dose of vinorelbine to 80 mg/m2 once weekly except in those patients for whom the neutrophil count dropped once <500/mm3 or more than once between 500 and 1,000/mm3 during the first three administrations at 60 mg/m2. <img src="/TGIF/Relvinca-Table1_120924.png" alt="Relvinca Dosage Table 1" /> </li> <li>Dose modification For any administration planned to be given at 80 mg/m2, if the neutrophil count is below 500/mm3, the administration should be delayed until recovery and the dose reduced from 80 to 60 mg/m2 per week during the 3 following administrations. <img src="/TGIF/Relvinca-Table2_120924.png" alt="Relvinca Dosage Table 2" /> It is possible to re-escalate the dose from 60 to 80 mg/m2 per week if the neutrophil count did not drop below 500/mm3 or more than once between 500 and 1,000/mm3 during 3 administrations given at 60 mg/m2 according to the rules previously defined for the first 3 administrations.</li> <li>For combination regimens, the dose and schedule will be adapted to the treatment protocol. Based on clinical studies, the oral dose of 80 mg/m2 was demonstrated to correspond to 30 mg/m2 of the IV form and 60 mg/m2 to 25 mg/m2. This has been the base for combination regimens alternating IV and oral forms improving patient convenience. For combination regimens, the dose and schedule will be adapted to the treatment protocol. The following table gives the dose required for appropriate ranges of body surface area (BSA). <img src="/TGIF/Relvinca-Table3_120924.png" alt="Relvinca Dosage Table 3" /> Even for patients with BSA≥ 2 m2 the total dose should never exceed 120 mg per week at 60 mg/m2 and 160 mg per week at 80 mg/m2.</li> </ul> Elderly Clinical experience has not detected any significant differences among elderly patients with regard to the response rate, although greater sensitivity in some of these patients cannot be excluded. Age does not modify the pharmacokinetics of vinorelbine (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Paediatric population Safety and efficacy in children have not been established and administration is therefore not recommended. (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Hepatic insufficiency Vinorelbine can be administered at the standard dose of 60 mg/m2/week in patients with mild liver impairment (bilirubin < 1.5 x ULN, and ALAT and/or ASAT from 1.5 to 2.5 x ULN). In patients with moderate liver impairment (bilirubin from 1.5 to 3 x ULN, whatever the levels of ALAT and ASAT), vinorelbine should be administered at a dose of 50 mg/m2/week. The administration of vinorelbine in patients with severe hepatic impairment is not recommended as there is insufficient data to determine the pharmacokinetics, efficacy and safety of vinorelbine in this population (see sections 4.3, 4.4, 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Renal insufficiency Given the minor renal excretion, there is no pharmacokinetic justification for reducing the dose of vinorelbine in patients with serious renal insufficiency (see sections 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Method of administration Vinorelbine must be given strictly by the oral route. Vinorelbine must be swallowed whole with water, without chewing, sucking or dissolving the capsule. It is recommended to administer the capsule with some food.
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic indications Vinorelbine is indicated in adults for: <ul> <li>Non-small cell lung cancer</li> <li>Advanced Breast Cancer.</li> </ul>
Contraindications: 4.3 Contraindications <ul class="dash"> <li>Hypersensitivity to the active substance, other vinca-alkaloids or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</li> <li>Disease significantly affecting absorption</li> <li>Previous significant surgical resection of stomach or small bowel.</li> <li>Neutrophil count <1,500/mm3 or severe infection current or recent (within 2 weeks).</li> <li>Platelet count <100,000/mm3</li> <li>Lactation (see section 4.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)</li> <li>Patients requiring long-term oxygen therapy</li> <li>In combination with yellow fever vaccine (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).</li> </ul>

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jul 31, 2025

Approval ID

d52855d9c5037367

Type

Therapeutic

Back to HSA Approvals